Lord Abbett Health Care F3 holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Lord Abbett Health Care Fund Class F3 LHCOX
- NAV / 1-Day Return 23.84 / +0.72 %
- Total Assets 8.7M
-
Adj. Expense Ratio
0.680%
- Expense Ratio 0.650%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.35%
- Turnover 91%
USD | NAV as of Jul 18, 2026 | 1-Day Return as of Jul 18, 2026, 12:12 AM GMT+0
Morningstar’s Analysis LHCOX
Will LHCOX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 43.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 10.78 | 856,375 | Healthcare |
AstraZeneca PLC | 4.75 | 377,133 | Healthcare |
Gilead Sciences Inc | 4.48 | 355,836 | Healthcare |
Guardant Health Inc | 4.01 | 318,908 | Healthcare |
UnitedHealth Group Inc | 3.91 | 310,713 | Healthcare |
Natera Inc | 3.24 | 257,099 | Healthcare |
Johnson & Johnson | 3.20 | 254,398 | Healthcare |
CVS Health Corp | 3.13 | 248,739 | Healthcare |
argenx SE | 2.79 | 222,024 | Healthcare |
Galderma Group AG Registered Shares | 2.75 | 218,283 | Healthcare |